Overview

A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy

Status:
Completed
Trial end date:
2016-08-18
Target enrollment:
Participant gender:
Summary
This is a prospective, observational, open-label, multi-center study, which will provide detailed information about the safety and efficacy of Twynsta tablets in Korean hypertensive patients requiring combination therapy. This will present a convenient treatment option for hypertension in Korean patients.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Amlodipine
Telmisartan
Telmisartan amlodipine combination